Third Rock Ventures Pumps $38 Million Into New Firm Focused On Genetic Heart Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
Third Rock is the sole Series A investor in MyoKardia, which plans to use personalized medicine to treat hypertrophic and dilated cardiomyopathies.
You may also be interested in...
Biopharma Dealmaking Quarterly Statistics, Q3 2012
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.
Start-Up Quarterly Statistics, Q3 2012
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
Financings Of The Fortnight Notices Autumn Coincides With Increase In Option Deals
Plus news on recent financings by MyoKardia, Biogen Idec, Annovation and Wellington Partners.